US Drug Recall Register

FDA Drug Recalls

11,815 recalls · Class II, newest first

Class II · Moderate risk Terminated

Flucanozole Tablets

Reason Failed Dissolution Specifications; 18 month stability time point

Dr. Reddy's Laboratories, Inc. NDC 55111-144-30 D-0450-2017
Class II · Moderate risk Terminated

Flucanozole Tablets

Reason Failed Dissolution Specifications; 18 month stability time point

Dr. Reddy's Laboratories, Inc. NDC 55111-143-30 D-0449-2017
Class II · Moderate risk Terminated

Clindamycin Phosphate and Benzoyl Peroxide Gel

Reason Microbial Contamination of Non-Sterile Product; small number of tubes may include the presence of mold on the cap

L. Perrigo Company NDC 45802-736-84 D-0434-2017
Class II · Moderate risk Terminated

Venlafaxine Hydrochloride extended release capsules

Reason Failed Tablet/Capsule Specifications: Some bottles contain punctured, and/or clumped/melted capsules.

Aurobindo Pharma USA Inc NDC 65862-527-30 D-0474-2017
Class II · Moderate risk Terminated

Furosemide Tablets USP

Reason Failed Tablet/Capsule Specifications: An unusually thick tablet was reported through a complaint.

Roxane Laboratories, Inc. NDC 0054-4297-31 D-0437-2017
Class II · Moderate risk Terminated

Nadolol Tablets

Reason Failed dissolution specification: recalled due to an out of specification dissolution result of 40% (Specification: NLT 80%)

Sandoz Incorporated NDC 0781-1182-10 D-0236-2017
Class II · Moderate risk Terminated

Amoxicillin for Oral Suspension USP

Reason Subpotency: due to a low, out of specification test result for assay during stability testing.

Teva Pharmaceuticals USA NDC 0093-4150-73 D-0440-2017
Class II · Moderate risk Terminated

Lisinopril tablets

Reason Failed tablet/capsule specification: missing break line on the 5mg tablet.

Accord Healthcare, Inc. NDC 16729-376-17 D-0478-2017
Class II · Moderate risk Terminated

Temozolomide Capsules

Reason Failed Tablet/Capsule Specifications: customer complaints of broken or crushed capsules, resulting in loose powder in the bottle.

Mylan LLC. NDC 0378-5265-98 D-0444-2017
Class II · Moderate risk Terminated

Temozolomide Capsules

Reason Failed Tablet/Capsule Specifications: customer complaints of broken or crushed capsules, resulting in loose powder in the bottle.

Mylan LLC. NDC 0378-5264-98 D-0443-2017
Class II · Moderate risk Terminated

Temozolomide Capsules

Reason Failed Tablet/Capsule Specifications: customer complaints of broken or crushed capsules, resulting in loose powder in the bottle.

Mylan LLC. NDC 0378-5263-98 D-0442-2017
Class II · Moderate risk Terminated

Temozolomide Capsules

Reason Failed Tablet/Capsule Specifications: customer complaints of broken or crushed capsules, resulting in loose powder in the bottle.

Mylan LLC. NDC 0378-5262-98 D-0441-2017
Class II · Moderate risk Terminated

Midazolam Injection

Reason Failed Impurities/Degradation Specifications

Fresenius Kabi USA, LLC NDC 63323-412-05 D-0456-2017
Class II · Moderate risk Terminated

AMGEN Kyprolis

Reason Lack of Assurance of Sterility: Potential cracks in glass vials

Amgen, Inc. NDC 76075-102-01 D-0226-2017
Class II · Moderate risk Terminated

Torsemide Tablets

Reason CGMP Deviations

Apotex Corp. NDC 60505-0232-01 D-0245-2017
Class II · Moderate risk Terminated

Torsemide Tablets

Reason CGMP Deviations

Apotex Corp. NDC 60505-0234-01 D-0244-2017
Class II · Moderate risk Terminated

10% Premasol sulfite-free

Reason Discoloration: there were customer reports of yellow discolored solution. The yellow coloration is the result of oxidation of the amino acid tryptophan due to a damaged overpouch.

Baxter Healthcare Corporation NDC 0338-1130-06 D-0425-2017
Class II · Moderate risk Terminated

Fluconazole Injection

Reason Lack of Assurance of Sterility: confirmed customer complaints of leaking bags.

Baxter Healthcare Corporation NDC 0338-6046-48 D-0206-2017